Purification and Characterization of Shiga Toxin 2f, an Immunologically Unrelated Subtype of Shiga Toxin 2

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Skinner, Craig ^a   McMahon, Stephanie ^a   Rasooly, Reuven ^a   Carter, John Mark ^a   He, Xiaohua ^a  

^a WESTERN REGIONAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLOBOTETRAOSE LIPOPOLYSACCHARIDE; GLOBOTRIOSE LIPOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE; UNCLASSIFIED DRUG; VEROTOXIN 2; VEROTOXIN 2A; VEROTOXIN 2F;

ANIMAL CELL; ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; BACTERIAL STRAIN; BINDING AFFINITY; CELL FREE SYSTEM; CONTROLLED STUDY; CYTOTOXICITY TEST; ENZYME ACTIVITY; ESCHERICHIA COLI; GEL FILTRATION; HYDROPHOBIC INTERACTION CHROMATOGRAPHY; ION EXCHANGE CHROMATOGRAPHY; MOLECULAR WEIGHT; NONHUMAN; PH; POLYACRYLAMIDE GEL ELECTROPHORESIS; PURIFICATION; RABBIT; RECEPTOR BINDING; RETICULOCYTE; THERMOSTABILITY; TOXIN ANALYSIS; VERO CELL;

AMMONIUM SULFATE; ANIMALS; CELL-FREE SYSTEM; CERCOPITHECUS AETHIOPS; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, ION EXCHANGE; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLOBOSIDES; HOT TEMPERATURE; HYDROGEN-ION CONCENTRATION; LIPOPOLYSACCHARIDES; PROTEIN BINDING; RABBITS; RECOMBINANT PROTEINS; SHIGA TOXIN 2; TRISACCHARIDES; VERO CELLS;

COLUMBA; ESCHERICHIA COLI; ORYCTOLAGUS CUNICULUS;

EID: 84875450016     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059760     Document Type: Article

References (43)

1. Cantey JR, (1985) Shiga toxin-an expanding role in the pathogenesis of infectious diseases. J Infect Dis 151: 766-771.
2. Quinones B, Swimley MS, (2011) Use of a Vero cell-based fluorescent assay to assess relative toxicities of Shiga toxin 2 subtypes from Escherichia coli. Methods Mol Biol 739: 61-71.
3. Mellmann A, Harmsen D, Cummings CA, Zentz EB, Leopold SR, et al. (2011) Prospective genomic characterization of the German enterohemorrhagic Escherichia coli O104: H4 outbreak by rapid next generation sequencing technology. PLoS One 6: e22751.
4. Bielaszewska M, Mellmann A, Zhang W, Kock R, Fruth A, et al. (2011) Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: a microbiological study. Lancet Infect Dis 11: 671-676.
5. Pai CH, Kelly JK, Meyers GL, (1986) Experimental infection of infant rabbits with verotoxin-producing Escherichia coli. Infect Immun 51: 16-23.
6. Feng PC, Jinneman K, Scheutz F, Monday SR, (2011) Specificity of PCR and serological assays in the detection of Escherichia coli Shiga toxin subtypes. Appl Environ Microbiol 77: 6699-6702.
7. Coombes BK, Gilmour MW, Goodman CD, (2011) The evolution of virulence in non-o157 shiga toxin-producing Escherichia coli. Front Microbiol 2: 90.
8. Beddoe T, Paton AW, Le Nours J, Rossjohn J, Paton JC, (2010) Structure, biological functions and applications of the AB5 toxins. Trends Biochem Sci 35: 411-418.
9. Shimizu T, Ohta Y, Noda M, (2009) Shiga toxin 2 is specifically released from bacterial cells by two different mechanisms. Infect Immun 77: 2813-2823.
10. Endo Y, Tsurugi K, Yutsudo T, Takeda Y, Ogasawara T, et al. (1988) Site of action of a Vero toxin (VT2) from Escherichia coli O157: H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur J Biochem 171: 45-50.
11. Bonyadian M, Momtaz H, Rahimi E, Habibian R, Yazdani A, et al. (2010) Identification & characterization of Shiga toxin-producing Escherichia coli isolates from patients with diarrhoea in Iran. Indian J Med Res 132: 328-331.
12. Gamage SD, Strasser JE, Chalk CL, Weiss AA, (2003) Nonpathogenic Escherichia coli can contribute to the production of Shiga toxin. Infect Immun 71: 3107-3115.
13. Plunkett G, 3rd, Rose DJ, Durfee TJ, Blattner FR (1999) Sequence of Shiga toxin 2 phage 933W from Escherichia coli O157: H7: Shiga toxin as a phage late-gene product. J Bacteriol 181: 1767-1778.
14. Law D, Ganguli LA, Donohue-Rolfe A, Acheson DW, (1992) Detection by ELISA of low numbers of Shiga-like toxin-producing Escherichia coli in mixed cultures after growth in the presence of mitomycin C. J Med Microbiol. 36: 198-202.
15. Zhang X, McDaniel AD, Wolf LE, Keusch GT, Waldor MK, et al. (2000) Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. J Infect Dis 181: 664-670.
16. Hertig A, Ridel C, Rondeau E, (2010) [Hemolytic uremic syndrome in adults]. Nephrol Ther 6: 258-271.
17. Scheutz F, Teel LD, Beutin L, Pierard D, Buvens G, et al. (2012) Multicenter evaluation of a sequence-based protocol for subtyping Shiga toxins and standardizing Stx nomenclature. J Clin Microbiol 50: 2951-2963.
18. Fuller CA, Pellino CA, Flagler MJ, Strasser JE, Weiss AA, (2011) Shiga toxin subtypes display dramatic differences in potency. Infect Immun 79: 1329-1337.
19. Tesh VL, Burris JA, Owens JW, Gordon VM, Wadolkowski EA, et al. (1993) Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice. Infect Immun 61: 3392-3402.
20. Bauwens A, Bielaszewska M, Kemper B, Langehanenberg P, von Bally G, et al. (2011) Differential cytotoxic actions of Shiga toxin 1 and Shiga toxin 2 on microvascular and macrovascular endothelial cells. Thromb Haemost 105: 515-528.
21. Friedrich AW, Bielaszewska M, Zhang WL, Pulz M, Kuczius T, et al. (2002) Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. J Infect Dis 185: 74-84.
22. Beutin L, Kruger U, Krause G, Miko A, Martin A, et al. (2008) Evaluation of major types of Shiga toxin 2e-producing Escherichia coli bacteria present in food, pigs, and the environment as potential pathogens for humans. Appl Environ Microbiol 74: 4806-4816.
23. Moxley RA, (2000) Edema disease. Vet Clin North Am Food Anim Pract 16: 175-185.
24. Schmidt H, Scheef J, Morabito S, Caprioli A, Wieler LH, et al. (2000) A new Shiga toxin 2 variant (Stx2f) from Escherichia coli isolated from pigeons. Appl Environ Microbiol 66: 1205-1208.
25. Prager R, Fruth A, Siewert U, Strutz U, Tschape H, (2009) Escherichia coli encoding Shiga toxin 2f as an emerging human pathogen. Int J Med Microbiol 299: 343-353.
26. He X, Quinones B, McMahon S, Mandrell RE, (2012) A single-step purification and molecular characterization of functional Shiga toxin 2 variants from pathogenic Escherichia coli. Toxins (Basel) 4: 487-504.
27. Paton AW, Morona R, Paton JC, (2000) A new biological agent for treatment of Shiga toxigenic Escherichia coli infections and dysentery in humans. Nat Med 6: 265-270.
28. Paton AW, Morona R, Paton JC, (2001) Neutralization of Shiga toxins Stx1, Stx2c, and Stx2e by recombinant bacteria expressing mimics of globotriose and globotetraose. Infect Immun 69: 1967-1970.
29. He X, Quinones B, Carter JM, Mandrell RE, (2009) Validation of a cell-free translation assay for detecting shiga toxin 2 in bacterial culture. J Agric Food Chem 57: 5084-5088.
30. Rasooly R, Do PM, Griffey SM, Vilches-Moure JG, Friedman M, (2010) Ingested Shiga toxin 2 (Stx2) causes histopathological changes in kidney, spleen, and thymus tissues and mortality in mice. J Agric Food Chem 58: 9281-9286.
31. MacLeod DL, Gyles CL, (1990) Purification and characterization of an Escherichia coli Shiga-like toxin II variant. Infect Immun 58: 1232-1239.
32. Downes FP, Barrett TJ, Green JH, Aloisio CH, Spika JS, et al. (1988) Affinity purification and characterization of Shiga-like toxin II and production of toxin-specific monoclonal antibodies. Infect Immun 56: 1926-1933.
33. Muthing J, Meisen I, Zhang W, Bielaszewska M, Mormann M, et al. (2012) Promiscuous Shiga toxin 2e and its intimate relationship to Forssman. Glycobiology 22: 849-862.
34. Di R, Kyu E, Shete V, Saidasan H, Kahn PC, et al. (2011) Identification of amino acids critical for the cytotoxicity of Shiga toxin 1 and 2 in Saccharomyces cerevisiae. Toxicon 57: 525-539.
35. He X, Qi W, Quinones B, McMahon S, Cooley M, et al. (2011) Sensitive detection of Shiga Toxin 2 and some of its variants in environmental samples by a novel immuno-PCR assay. Appl Environ Microbiol 77: 3558-3564.
36. Marcato P, Mulvey G, Read RJ, Vander Helm K, Nation PN, et al. (2001) Immunoprophylactic potential of cloned Shiga toxin 2 B subunit. J Infect Dis 183: 435-443.
37. Lentz EK, Leyva-Illades D, Lee MS, Cherla RP, Tesh VL, (2011) Differential response of the human renal proximal tubular epithelial cell line HK-2 to Shiga toxin types 1 and 2. Infect Immun 79: 3527-3540.
38. Schuller S, (2011) Shiga toxin interaction with human intestinal epithelium. Toxins (Basel) 3: 626-639.
39. Sonntag AK, Bielaszewska M, Mellmann A, Dierksen N, Schierack P, et al. (2005) Shiga toxin 2e-producing Escherichia coli isolates from humans and pigs differ in their virulence profiles and interactions with intestinal epithelial cells. Appl Environ Microbiol 71: 8855-8863.
40. Lingwood CA, (1996) Role of verotoxin receptors in pathogenesis. Trends Microbiol 4: 147-153.
41. Tyrrell GJ, Ramotar K, Toye B, Boyd B, Lingwood CA, et al. (1992) Alteration of the carbohydrate binding specificity of verotoxins from Gal alpha 1-4Gal to GalNAc beta 1-3Gal alpha 1-4Gal and vice versa by site-directed mutagenesis of the binding subunit. Proc Natl Acad Sci U S A 89: 524-528.
42. Asahara T, Shimizu K, Nomoto K, Hamabata T, Ozawa A, et al. (2004) Probiotic bifidobacteria protect mice from lethal infection with Shiga toxin-producing Escherichia coli O157: H7. Infect Immun 72: 2240-2247.
43. Steinberg KM, Levin BR, (2007) Grazing protozoa and the evolution of the Escherichia coli O157: H7 Shiga toxin-encoding prophage. Proc Biol Sci 274: 1921-1929.